textochbilcontainer
A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT
textochbilcontainer
OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700
textochbilcontainer
Moberg pharma intends to submit a registration application in Europe in 2021.
textochbilcontainer
We support Barncancerfonden
Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.
32,90 kr
+2,5 %
- All pressreleases
- Regulatory
Subscribe
Latest report
2020-11-10 Extended fiscal year July 2019 - December 2020 Interim report July – September 2020RIGHTS ISSUE 2020
Moberg Pharma conducts a fully guaranteed rights issue in 2020, read more here
SPIN-OFF AND SEPARATE LISTING OF BUPI Q1 2021
Moberg Pharma has announced its intention to distribute the operations of BupiZenge® (BUPI) to the shareholders of Moberg Pharma by distributing its shares in the subsidiary OncoZenge AB through a Lex ASEA distribution before listing the OncoZenge on Nasdaq First North Growth Market in Q1 2021. Read more at OncoZenges webpage
